<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146522</url>
  </required_header>
  <id_info>
    <org_study_id>CLCQ908A2212</org_study_id>
    <nct_id>NCT01146522</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia</brief_title>
  <official_title>A Multiple-dose, Parallel Group Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCQ908 in Patients With Severe Hypertriglyceridemia and Chylomicronemia (Phenotypes I and V)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess safety, tolerability, and effect of LCQ908 on blood lipids in patients
      with severe hypertriglyceridemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting and postprandial plasma triglycerides</measure>
    <time_frame>baseline and 3 weeks after initiation of each dose level (a test meal will be served at baseline and on Day 21 of treatment)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood concentration to characterize LCQ908 kinetics</measure>
    <time_frame>serial blood samples will be collected from all patients enrolled in the study on Day 21 of treatment with each dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Different blood lipid biomarkers (such as phospholipids, apolipoproteins, and free fatty acids)</measure>
    <time_frame>after 3 weeks of treatment with each dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Hyperlipoproteinemia</condition>
  <arm_group>
    <arm_group_label>LCQ908</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCQ908</intervention_name>
    <arm_group_label>LCQ908</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hyperlipoproteinemia Type I or Type V willing and medically able to
             discontinue their lipid lowering medication (if prescribed).

          -  Non breast feeding women.

          -  Women of child bearing potential practicing appropriate contraception with a negative
             pregnancy test before dosing.

        Exclusion Criteria:

        Patients with:

          -  uncontrolled type 1 or type 2 diabetes mellitus,

          -  active pancreatitis (the month prior to study start),

          -  history of drug or alcohol abuse within the 12 months prior to dosing,

          -  or any surgical or medical condition, acute or unstable chronic disease which may,
             based on the investigator's opinion, jeopardize the patient in case of participation
             in the study.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>June 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2010</study_first_posted>
  <disposition_first_submitted>November 30, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 30, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 4, 2012</disposition_first_posted>
  <last_update_submitted>December 28, 2012</last_update_submitted>
  <last_update_submitted_qc>December 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Familial hyperchylomicronemia</keyword>
  <keyword>Lipoprotein lipase deficiency</keyword>
  <keyword>Hyperlipoproteinemia</keyword>
  <keyword>Triglycerides</keyword>
  <keyword>Hypertriglyceridemia</keyword>
  <keyword>LCQ908</keyword>
  <keyword>Hyperlipoproteinemia associated with lipoprotein lipase deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

